Patient-centred research provides a better understanding of the impact of bottle modifications on glaucoma patients

Article

Sponsored Feature. Xalatan® is to become available across Europe in a newly designed bottle. So what does that mean and what lies behind that decision?

Recent Videos
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Vikas Chopra at AAO 2024: Advancements in MIGS are transforming patient care
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Related Content
A sign outside the US Food and Drug Administration headquarters. Image credit: ©Tada Images – stock.adobe.com

US FDA approves Zeiss MEL 90 excimer laser for myopia, hyperopia and mixed astigmatism

Jordana Joy
January 14th 2025
Article

The laser integrates into the Corneal Refractive Workflow alongside the Visumax 800 and SMILE pro software

PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

July 25th 2024
Podcast

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

Bausch + Lomb launches its enVista Aspire monofocal and toric intraocular lenses in the European Union

Bausch + Lomb launches its enVista Aspire monofocal and toric intraocular lenses in the European Union

Martin David Harp
January 13th 2025
Article

The launch follows a CE Mark received in late 2024

PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

July 24th 2024
Podcast

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

A mother who has recently given birth looks at her baby, who rests in an incubator. Image credit: ©Richard Semik – stock.adobe.com

Retinopathy of prematurity study demonstrates noninferiority of combination microdrops compared to standard mydriatics

Lynda Charters
January 10th 2025
Article

The authors investigated systemic adverse events associated with commercial mydriatics administered during retinopathy of prematurity (ROP) screening

A gloved hand, holding a syringe, is pictured next to a US FDA (Food and Drug Administration) logo. Image credit: ©ra2 studio – stock.adobe.com

ViGeneron receives rare paediatric disease designation from US FDA for retinitis pigmentosa gene therapy candidate VG901

Hattie Hayes
January 9th 2025
Article

ViGeneron, based in Munich, also received approval for dose escalation in the ongoing phase 1b clinical trial

© 2025 MJH Life Sciences

All rights reserved.